🔗 Share this article

This year's prestigious award in medical science has been granted for transformative discoveries that illuminate how the body's defense network attacks harmful pathogens while protecting the healthy tissues.

A trio of renowned researchers—Japan's Shimon Sakaguchi and US scientists Mary Brunkow and Fred Ramsdell—received this accolade.

The work uncovered specialized "sentinels" within the immune system that remove rogue immune cells that could harming the body.

The findings are now paving the way for innovative treatments for immune disorders and malignancies.

These winners will divide a prize fund valued at 11m Swedish kronor.

Crucial Findings

"The work has been decisive for comprehending how the immune system operates and the reason we do not all suffer from severe self-attack conditions," stated the head of the award panel.

The trio's studies address a fundamental question: How does the immune system defend us from countless invaders while leaving our own tissues unharmed?

The body's protection system employs immune cells that search for indicators of disease, even pathogens and germs it has never encountered.

Such defenders utilize detectors—called receptors—that are generated randomly in a vast number of variations.

That gives the defense network the ability to fight a wide array of invaders, but the unpredictability of the mechanism inevitably produces immune cells that may target the body.

Security Guards of the Body

Researchers previously understood that some of these harmful white blood cells were destroyed in the immune organ—where white blood cells mature.

This year's Nobel Prize recognizes the discovery of regulatory T-cells—described as the body's "peacekeepers"—which patrol the body to disarm any immune cells that assault the healthy cells.

It is known that this mechanism malfunctions in self-attack conditions such as type-1 diabetes, MS, and rheumatoid arthritis.

The prize committee added, "The findings have established a novel area of research and spurred the development of new treatments, for instance for cancer and autoimmune diseases."

In malignancies, regulatory T-cells prevent the system from fighting the growth, so studies are aimed at lowering their numbers.

In autoimmune diseases, experiments are testing increasing regulatory T-cells so the body is no longer being harmed. A comparable method could also be useful in reducing the risks of transplanted organ rejection.

Innovative Studies

Professor Sakaguchi, from Osaka University, conducted experiments on mice that had their thymus extracted, leading to autoimmune disease.

He showed that introducing immune cells from other mice could prevent the illness—suggesting there was a system for preventing defenders from attacking the host.

Dr. Brunkow, from the a research center in Seattle, and Fred Ramsdell, now at a biotech firm in San Francisco, were investigating an inherited autoimmune disease in rodents and people that resulted in the discovery of a genetic factor vital for how T-regs operate.

"The groundbreaking work has revealed how the immune system is kept in check by regulatory T cells, stopping it from mistakenly targeting the body's own tissues," said a prominent physiology expert.

"This research is a remarkable example of how fundamental biological study can have broad implications for public health."